S
Scott Baumgartner
Researcher at Amgen
Publications - 66
Citations - 7410
Scott Baumgartner is an academic researcher from Amgen. The author has contributed to research in topics: Etanercept & Rheumatoid arthritis. The author has an hindex of 27, co-authored 64 publications receiving 7092 citations. Previous affiliations of Scott Baumgartner include Université de Montréal & Ironwood Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Larry W. Moreland,Scott Baumgartner,Michael Schiff,Elizabeth A. Tindall,Roy Fleischmann,Arthur L. Weaver,Robert E. Ettlinger,Stanley Cohen,William J. Koopman,Kendall Mohler,Michael B. Widmer,Consuelo M. Blosch +11 more
TL;DR: In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
Journal ArticleDOI
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Larry W. Moreland,Michael Schiff,Scott Baumgartner,Elizabeth A. Tindall,Roy Fleischmann,Ken J. Bulpitt,Arthur L. Weaver,Edward C. Keystone,Daniel E. Furst,Philip J. Mease,Eric Ruderman,David A. Horwitz,Daniel G. Arkfeld,Leslie Garrison,Daniel Burge,Consuelo M. Blosch,Mary Lange,Neil D. McDonnell,Michael E. Weinblatt +18 more
TL;DR: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months as discussed by the authors.
Journal ArticleDOI
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Kim A. Papp,Craig L. Leonardi,Alan Menter,Jean-Paul Ortonne,James G. Krueger,Gregory Kricorian,Girish A. Aras,Juan Li,Chris B. Russell,Elizabeth H.Z. Thompson,Scott Baumgartner +10 more
TL;DR: Bdalumab significantly improved plaque psoriasis in this 12-week, phase 2 study and was superior to placebo in all comparisons.
Journal Article
Etanercept Therapy in Rheumatoid Arthritis
Larry W. Moreland,Michael Schiff,Scott Baumgartner,Elizabeth A. Tindall,Roy Fleischmann,Ken J. Bulpitt,Arthur L. Weaver,Edward C. Keystone,Daniel E. Furst,Philip J. Mease,Eric Ruderman,David A. Horwitz,Daniel G. Arkfeld,Leslie Garrison,Daniel Burge,Consuelo M. Blosch,Mary Lange,Neil D. McDonnell,Michael E. Weinblatt +18 more
TL;DR: This study sought to define further the clinical activity of etanercept over a longer treatment period and to establish a simplified dosing schema for rheumatoid arthritis.
Journal ArticleDOI
Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
Daniel J. Lovell,Andreas Reiff,Andreas Reiff,Norman T. Ilowite,Carol A. Wallace,Yun Chon,Shao Lee Lin,Scott Baumgartner,Edward H. Giannini +8 more
TL;DR: These data suggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in this population of JRA patients.